Evidence map›Paper›PMID 23399357›Full record

ArticleBlood transfusion = Trasfusione del sangue2014

Bio-modulators in platelet-rich plasma: a comparison of the amounts in products from healthy donors and patients produced with three different techniques.

Gianluca Ubezio, Massimo Ghio, Paola Contini, Roberta Bertorello, Gennaro Marino, Andrea Tomasini, Gino Tripodi

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood transfusion = Trasfusione del sangue, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. A review of platelet-rich plasma for enteric fistula management.Frontiers in bioengineering and biotechnology · 2023
    Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Gianluca UbezioDepartment of Internal Medicine, I.R.C.C.S. "A.O.U. San Martino-IST" and University of Genoa, Genoa, Italy.
Massimo GhioDepartment of Internal Medicine, I.R.C.C.S. "A.O.U. San Martino-IST" and University of Genoa, Genoa, Italy.
Paola ContiniDepartment of Internal Medicine, I.R.C.C.S. "A.O.U. San Martino-IST" and University of Genoa, Genoa, Italy.
Roberta BertorelloImmunohaematology and Transfusion Medicine Unit, Santa Corona Hospital ASL2, Savona, Italy.
Gennaro MarinoImmunohaematology and Transfusion Medicine Unit, Santa Corona Hospital ASL2, Savona, Italy.
Andrea TomasiniImmunohaematology and Transfusion Medicine Unit, Santa Corona Hospital ASL2, Savona, Italy.
Gino TripodiImmunohematology and Transfusion Centre, Istituto Giannina Gaslini, Genoa, Italy.
Martin University · USOspedale Santa Corona · ITIstituto Giannina Gaslini · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPlatelet-rich plasma consists of platelets concentrated in a small volume of plasma and constitutes a reservoir of bio-modulators potentially useful in tissue repair. The amounts of bio-modulators detectable in platelet-rich plasma prepared with various commercial or "in house" methods have been reported, but virtually all the analyses described have been performed on platelet-rich plasma derived from healthy donors. Since leucocyte contamination is technically unavoidable, we investigated whether platelet-rich plasma prepared from patients could contain different amounts of bio-modulators because of a possible activated status of the leucocytes. MATERIALS AND

methodsWe evaluated platelet-rich plasma prepared with three different techniques (the commercial Vivostat and Biomet recover GPS II systems and an "in house" method) starting from whole blood from healthy donors and patients. Specifically, we compared the levels of sHLA-I, sFasL, platelet-derived growth factor, transforming growth factors-beta and vascular endothelial growth factor in the platelet-rich plasma releasates according to the method of preparation and to the immune system activation status of the subjects.

resultsWith the exception of sHLA-I levels, no differences were found in the surrogate indices of lymphocyte activation between healthy donors and patients. No significant differences were found in sHLA-I, sFasL, platelet-derived growth factor, transforming growth factors-beta and vascular endothelial growth factor levels detectable in platelet-rich plasma produced with the three different methods in either healthy donors or patients. DISCUSSION: On the whole our findings indicate that the overall content of bio-modulators in autologous platelet-rich plasma is not influenced by T-lymphocyte activation status, at least in patients with uncomplicated femoral fractures. The amounts of sFasL and sHLA-I detected in all the platelet-rich plasma releasates studied were very small, far below the amounts detectable in all clinically available blood derivatives and absolutely insufficient to induce sHLA-I and/or sFasL mediated immunomodulation.

Indexed as

Blood DonorsPlatelet-Rich PlasmaAdultAnticoagulantsBatroxobinBlood Component RemovalBlood PreservationBlood Transfusion, AutologousCitric AcidFas Ligand ProteinFibrinGelsGlucoseHLA AntigensHumansIntercellular Signaling Peptides and Proteinsacid citrate dextroseAnticoagulantsBatroxobinCitric AcidFASLG protein, humanFas Ligand ProteinFibrinGelsGlucoseHLA AntigensIntercellular Signaling Peptides and Proteins

Identifiers

PMID23399357
PMCPMC3934217
OpenAlexW1596733714

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.